Background. The type-2 sodium-glucose cotransporters inhibitors (SGLT2i) are a new relevant therapeutic option for patients affected by chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the clinical characteristics and therapy of HFrEF patients undergoing SGLT2i therapy.
Methods. We evaluated the consecutive patients affected by HFrEF in whom the SGLT2i therapy was prescribed since December 2021. At baseline clinical visit, ECG, echocardiography, assessment of sodium, potassium, fasting glucose, hemoglobin, hematocrit, glomerular filtration rate (GFR) by creatinine were assessed.
Results. Ninety patients were enrolled. In the Table clinical characteristics and therapy are reported. Interestingly, most of patients were already trated with the classes of drugs currently recommended fo HFrEF treatment.
Conclusions. In this “real world” study, SGLT2i were prescribed in HFrEF patients most of all already in therapy with the other classes of drugs currently recommended for their treatment. These data further support the use of this therapeutic approach in routine clinical practice.